Pacira Pharmaceuticals' Exparel (bupivacaine liposome injectable emulsion) has a complex patent landscape that extends beyond 2025. While some foundational patents may expire around that time, other patents covering different aspects of the drug's formulation, method of use, and manufacturing processes are in place.
When does Exparel's core patent protection end?
The original patent for Exparel's formulation is expected to expire in 2025 [1]. However, this does not mean that generic versions will immediately become available.
Are there other patents protecting Exparel?
Yes, Pacira has secured numerous additional patents. These patents cover various aspects, including specific formulations, methods of manufacturing, and methods of use for different medical procedures [2]. DrugPatentWatch.com tracks these patents and their expiration dates, indicating that some protections extend much further into the future [1].
What are the implications of these multiple patents for generic competition?
The existence of multiple patents, often referred to as "patent thickets," can make it challenging for generic manufacturers to enter the market even after a primary patent expires. Generic companies typically need to navigate these patents and may face patent litigation from Pacira if they attempt to launch a product that infringes on any of the active patents [3].
How long will Exparel likely remain off-patent?
Based on the patent filings tracked by DrugPatentWatch.com, Exparel's market exclusivity is anticipated to last for many years beyond 2025 due to the layered patent strategy [1]. The exact duration depends on the validity and enforceability of each patent and any potential legal challenges.
What is Pacira's strategy regarding Exparel patents?
Pacira has actively pursued and defended its intellectual property for Exparel, utilizing a strategy of obtaining numerous patents to extend market exclusivity. This approach is common in the pharmaceutical industry to protect significant investments in drug development and commercialization.
What is Exparel used for?
Exparel is a non-opioid analgesic indicated for infiltration and intra-articular injection to provide post-surgical analgesia [4]. It is used in various surgical settings to manage pain after procedures.
How does Exparel work?
Exparel is a liposome injectable emulsion that encapsulates bupivacaine, a local anesthetic. The liposomal encapsulation allows for the extended release of bupivacaine, providing pain relief for a longer duration compared to standard bupivacaine formulations [4].
Sources
1. DrugPatentWatch.com. (n.d.). Exparel Patent Expirations. Retrieved from https://drugpatentwatch.com/
2. Pacira Pharmaceuticals. (n.d.). Investor Relations. (Information on patent portfolio generally discussed in financial reports and SEC filings).
3. Pharmaceutical Technology. (n.d.). Patent challenges and litigation in the pharmaceutical industry.
4. Exparel Prescribing Information. (n.d.).